---
document_datetime: 2023-09-21 18:11:40
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/clopidogrel-acino-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: clopidogrel-acino-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.1319066
conversion_datetime: 2025-12-23 07:11:08.089322
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Clopidogrel Acino

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                                                                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary   |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------------------------|----------------------------------|-----------|
| IB/0018/G            | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a product | 05/01/2016                          | 28/01/2016                                     | SmPC and PL                      |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

Medicinal product no longer authorised

+44 (0)20 3660 6000

Facsimile

<!-- image -->

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                   | generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.z - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Other variation   |                          | longer      | authorised                        |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|-------------|-----------------------------------|
| IB/0017           | To update of section 4.8 of the SmPC to add 2 new undesirable effects: \"Acutegeneralised exanthematous pustulosis' (AGEP) and \"Gynaecomastia\" in line with originator changes. The Package Leaflet has been updated accordingly. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH Medicinal product                                                                                                                                    | 28/05/2015 28/01/2016 no | SmPC and PL |                                   |
| PSUSA/820/2 01311 | Periodic Safety Update EU Single assessment - ACETYLSALICYLIC ACID, CLOPIDOGREL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 10/07/2014               | n/a         | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IAIN/0016   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                                                                          | 27/06/2014   | n/a        |                                                               |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|---------------------------------------------------------------|
| IB/0015/G   | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the | 24/04/2014   | no longer  | authorised                                                    |
| R/0012      | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 23/01/2014   | 21/03/2014 | The CHMP recommended renewal for an unlimited period of time. |
| IB/0013     | MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH Medicinal product                                                                                                                                                                                                                                                                                       | 26/11/2013   | 21/03/2014 |                                                               |
| IB/0011/G   | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 10/10/2013   | 21/03/2014 |                                                               |

<div style=\"page-break-after: always\"></div>

|           | generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                  | authorised                                                       |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------|
| IB/0010/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH product | 13/08/2013 21/03/2014 SmPC, Annex II, Labelling and PL no longer |
| IAIN/0009 | B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer Medicinal                                                                                                                                                                                                                                                                                                                                 | 04/04/2012 n/a                                                   |
| T/0008    | Transfer of a marketing authorisation for Clopidogrel Acino 75 mg film-coated tablets                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 30/01/2012 06/03/2012 SmPC, Labelling and                        |

<div style=\"page-break-after: always\"></div>

|         | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                   | PL                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0007 | To update section 4.2 \"Posology and method of administration\" and 5.1 \"Pharmacodynamic properties\" of clopidogrel SPC to include new paediatric information available for clopidogrel. Minor linguistic changes have been introduced in the product information, to bring the product in line with the reference product. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                                                                                                                                                                                                      | 22/07/2011 n/a    | SmPC longer           | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IB/0006 | To update the Summary of Product Characteristics (SmPC) and Package Leaflet to update sections 4.2 \"Posology and method of administration\", 4.4 \"Special warnings and precautions for use\", 4.5 \"Interaction with other medicinal products and other forms of interaction\" and 5.2 \"Pharmacokinetic properties\" of clopidogrel/acetylsalicylic acid (ASA) SPC to include new information on the variability of response to clopidogrel due to either genetic variations of the CYP2C19 enzyme or concomitant use of drugs that inhibit the CYP2C19 enzyme such as proton pump inhibitor (PPI). In addition, section 4.8 has been amended with minor details on the CURE study. Additional changes have been added to the SmPC and Package Leaflet in order to bring it in line with the revised QRD template (version 7.3) In addition, the Medicinal product | 29/04/2011 n/a no | SmPC, Annex II and PL | To update the Summary of Product Characteristics (SmPC) and Package Leaflet to update sections 4.2 \"Posology and method of administration\", 4.4 \"Special warnings and precautions for use\", 4.5 \"Interaction with other medicinal products and other forms of interaction\" and 5.2 \"Pharmacokinetic properties\" of clopidogrel/acetylsalicylic acid (ASA) SPC to include new information on the variability of response to clopidogrel due to either genetic variations of the CYP2C19 enzyme or concomitant use of drugs that inhibit the CYP2C19 enzyme such as proton pump inhibitor (PPI). In addition, section 4.8 has been amended with minor details on the CURE study. Additional changes have been added to the SmPC and Package Leaflet in order to bring it in line with the revised QRD template (version 7.3) In addition, the deletion of DDPS number version and date was introduced in Annex IIB as requested by the EMA with the procedural |

<div style=\"page-break-after: always\"></div>

|          | deletion of DDPS number version and date was introduced in Annex IIB as requested by the EMA with the procedural announcement in October and November 2010. Minor linguistic changes have been introduced in the product information, to bring the product in line with the reference product. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH   |            |               | longer                 | announcement in October and November 2010. Minor linguistic changes have been introduced in the product information, to bring the product in line with the reference product. authorised                                                                                                                                                                                                                                                                                                           |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| A20/0004 | Pursuant to Article 20 of Regulation (EC) No 726/2004 of 31 March 2004, the European Commission requested on 18 March 2010, the opinion of the CHMP on measures necessary to ensure the quality of the above mentioned medicinal product further to GMP deficiencies of the API manufacturing site Glochem Industries Ltd. (Unit II). product                                                                                                                                                                                                   | 18/03/2010 | 16/09/2010 no |                        | Please refer to the Assessment Report: Clopidogrel Acino-H-1166-A20-04-Assessment Report-Article 20                                                                                                                                                                                                                                                                                                                                                                                                |
| IB/0005  | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO Medicinal                                                                                      | 06/08/2010 | n/a           | SmPC, Labelling and PL | To include information on the clopidogrel metabolism pathway, the role of CYP2C19 genetic polumorphism on clopidogrel variability of response and the potential interaction between clopidogrel and CYP2C19 inhibitors including some proton pump inhibitors. The MAH also took the oportunity to make align to the originator products. Furthermore the list of local representatives was deleted from the Package Leaflet. Additionally, the marketing authorisation number and date were added. |

<div style=\"page-break-after: always\"></div>

|         | new additional data are submitted by the MAH                                                                                                                                                                  |                                  |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|
| II/0003 | To register a revised version of the ASMF for clopidogrel besilate from the existing active substance manufacturer, introducing changes in the manufacturing process of the active substance. Quality changes | 21/01/2010 02/02/2010 authorised |
| II/0002 | To introduce a new active substance manufacturer. Quality changes                                                                                                                                             | 21/01/2010 02/02/2010 n/a longer |
| IA/0001 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site IA_07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms                                              | 13/11/2009 no                    |

Medicinal product no longer authorised